In this review, we discuss the interaction between cancer and markers of inflammation (such
as levels of inflammatory cells and proteins) in the circulation, and the potential benefits of …

Respiratory diseases, always being a threat towards the health of people all over the world,
are most tightly associated with immune system. Neutrophils serve as an important …

Objective The aim of this study was to identify baseline peripheral blood biomarkers
associated with clinical outcome in patients with NSCLC treated with nivolumab. Methods …

Background Tumor orchestrated metabolic changes in the microenvironment limit
generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino …

Abstract Introduction Programmed death-1 (PD-1) axis inhibitors have become standard
therapy in advanced non–small-cell lung cancer (NSCLC). Response might be delayed and …

Background: Recent studies have demonstrated the predictive value of pretreatment
neutrophil-to-lymphocyte ratio (NLR) in advanced cancers; however, the role of NLR in …

Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival
gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of …

Systemic inflammation is present during and serves as a diagnostic tool for cancer-
associated cachexia and is detrimental to serum 25-hydroxyvitamin D (25 (OH) D) …

Haemogram assessment is a cheap and easy method which can be readily performed for
almost all patients. Leucocyte, neutrophil and lymphocyte counts and the neutrophil to …

Cancer cachexia is characterized by the loss of lean body mass with or without the loss of fat
and is associated with increased susceptibility to treatment related toxicities, decreased …